Journal
JOURNAL OF CYSTIC FIBROSIS
Volume 10, Issue -, Pages S146-S151Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S1569-1993(11)60019-2
Keywords
Antimicrobial treatment; Drug development; Microbiome; Susceptibility testing
Categories
Funding
- European Union [LSHM-CT-2005-018932]
Ask authors/readers for more resources
Chronic infection of the respiratory tract is a hallmark of cystic fibrosis (CF). Antibiotic treatment has been used as one of the mainstays of therapy and together with other treatment modalities has resulted in increased survival of CF patients. Increasing resistance of CF-specific pathogens to various classes of antibiotics explains the need for novel antibiotic strategies. This review focuses on the future development of new antibiotic therapies, including: (I) New targets, (2) novel antibiotic regimens in CF, (3) new antibiotics, and (4) other investigational therapies. In addition, we briefly summarize developments in the area of microbial diagnostics and discuss interactions between the complex pulmonary microflora. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available